𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Importance of Within Subject Variation in Levodopa Pharmacokinetics: A 4Year Cohort Study in Parkinson’s Disease

✍ Scribed by Phylinda L. S. Chan; John G. Nutt; Nicholas H. G. Holford

Publisher
Springer
Year
2005
Tongue
English
Weight
279 KB
Volume
32
Category
Article
ISSN
1573-8744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A clinical and pharmacokinetic case stud
A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease
✍ G. K. Wenning; M. T. O'Connell; P. N. Patsalos; Dr. N. P. Quinn 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract We studied the relationship between levodopa response and antituberculous treatment in a patient with idiopathic Parkinson's disease whose parkinsonism deteriorated when treatment with rifampicin and isoniazid (Rifinah) for pulmonary tuberculosis was started. A levodopa challenge test w

Ropinirole in the treatment of early Par
Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
✍ Dr. Olivier Rascol; David J. Brooks; Ehrout R. Brunt; Amos D. Korczyn; Warner H. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 785 KB

The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5-year, double-blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson

Safety of entacapone and apomorphine coa
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic